Biotech Startups
10,099 companies tagged Biotech, with their investors and founders.
0 investors
SymKardia develops a selective cardiac neuromodulation therapy to treat cardiac arrhythmias such as atrial fibrillation, targeting the nervous system rather than only cardiac tissue. It is a clinical-stage cardiovascular medical device company running pre-clinical and clinical research programs.
0 investors
0 investors
0 investors
Synata Bio develops customizable technology solutions for hydrogen and carbon economies, enabling hard-to-abate industries to achieve decarbonization targets while reducing carbon emissions and creating value from waste resources.
0 investors
0 investors
0 investors
0 investors
0 investors
Syncromune develops SYNC-T, an investigational in situ personalized combination immunotherapy platform designed to treat metastatic solid tumors by synchronizing patient-specific tumor antigens with immune modulatory biologics. The company's lead candidate, SV-102, is in Phase 2 clinical trials for metastatic castration-resistant prostate cancer.
0 investors
0 investors
Synedgen develops first-in-class glycomics-based regenerative therapeutics that repair mucosal injury and restore barrier function. Its lead asset, MIIST305, is an orally delivered therapeutic that repairs gastrointestinal mucosal injury and reduces inflammation.
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
Synthonics develops Metal Coordination Pharmaceuticals (MCPs), which chelate metal ions to known drugs to improve properties such as absorption, efficacy, and onset of action. The company holds four US patents for its MCP technologies and works in the pharmaceutical and biotech industry.
0 investors
Syntr Health Technologies makes the SyntrFuge System, an FDA-cleared device that automates the processing of autologous fat (microfat) for fat grafting, body contouring, and tissue healing. The device is aimed at clinical practices—including plastic, orthopedic, wound care, gastrointestinal, and veterinary surgeons—enabling in-office fat transfer procedures.
0 investors
Syrna Therapeutics is a biotech company developing small-molecule covalent translation inhibitors that bind and modify structured domains in the mRNA of disease-causing proteins to block their expression. It uses a 3D structure-guided drug discovery platform, with lead programs in immunology and neurodegeneration and a broader pipeline spanning metabolic disease and oncology.
0 investors
0 investors